Cargando…
Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients
Finding cytokine storm initiator factors associated with uncontrolled inflammatory immune response is necessary in COVID-19 patients. The aim was the identification of Fas/Fas Ligand (FasL) role in lung involvement and mortality of COVID-19 patients. In this case-control study, mild (outpatient), mo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471328/ https://www.ncbi.nlm.nih.gov/pubmed/36119078 http://dx.doi.org/10.3389/fimmu.2022.947401 |
_version_ | 1784789048569626624 |
---|---|
author | Saleki, Kiarash Shirzad, Moein Javanian, Mostafa Mohammadkhani, Sheyda Alijani, Mohammad Hossein Miri, Niloufarsadat Oladnabi, Morteza Azadmehr, Abbas |
author_facet | Saleki, Kiarash Shirzad, Moein Javanian, Mostafa Mohammadkhani, Sheyda Alijani, Mohammad Hossein Miri, Niloufarsadat Oladnabi, Morteza Azadmehr, Abbas |
author_sort | Saleki, Kiarash |
collection | PubMed |
description | Finding cytokine storm initiator factors associated with uncontrolled inflammatory immune response is necessary in COVID-19 patients. The aim was the identification of Fas/Fas Ligand (FasL) role in lung involvement and mortality of COVID-19 patients. In this case-control study, mild (outpatient), moderate (hospitalized), and severe (ICU) COVID-19 patients and healthy subjects were investigated. RNA isolated from PBMCs for cDNA synthesis and expression of mFas/mFasL mRNA was evaluated by RT-PCR. Serum sFas/sFasL protein by ELISA and severity of lung involvement by CT-scan were evaluated. Also, we docked Fas and FasL via Bioinformatics software (in silico) to predict the best-fit Fas/FasL complex and performed molecular dynamics simulation (MDS) in hyponatremia and fever (COVID-19 patients), and healthy conditions. mFasL expression was increased in moderate and severe COVID-19 patients compared to the control group. Moreover, mFas expression showed an inverse correlation with myalgia symptom in COVID-19 patients. Elevation of sFasL protein in serum was associated with reduced lung injury and mortality. Bioinformatics analysis confirmed that blood profile alterations of COVID-19 patients, such as fever and hyponatremia could affect Fas/FasL complex interactions. Our translational findings showed that decreased sFasL is associated with lung involvement; severity and mortality in COVID-19 patients. We think that sFasL is a mediator of neutrophilia and lymphopenia in COVID-19. However, additional investigation is suggested. This is the first report describing that the serum sFasL protein is a severity and mortality prognostic marker for the clinical management of COVID-19 patients. |
format | Online Article Text |
id | pubmed-9471328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94713282022-09-15 Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients Saleki, Kiarash Shirzad, Moein Javanian, Mostafa Mohammadkhani, Sheyda Alijani, Mohammad Hossein Miri, Niloufarsadat Oladnabi, Morteza Azadmehr, Abbas Front Immunol Immunology Finding cytokine storm initiator factors associated with uncontrolled inflammatory immune response is necessary in COVID-19 patients. The aim was the identification of Fas/Fas Ligand (FasL) role in lung involvement and mortality of COVID-19 patients. In this case-control study, mild (outpatient), moderate (hospitalized), and severe (ICU) COVID-19 patients and healthy subjects were investigated. RNA isolated from PBMCs for cDNA synthesis and expression of mFas/mFasL mRNA was evaluated by RT-PCR. Serum sFas/sFasL protein by ELISA and severity of lung involvement by CT-scan were evaluated. Also, we docked Fas and FasL via Bioinformatics software (in silico) to predict the best-fit Fas/FasL complex and performed molecular dynamics simulation (MDS) in hyponatremia and fever (COVID-19 patients), and healthy conditions. mFasL expression was increased in moderate and severe COVID-19 patients compared to the control group. Moreover, mFas expression showed an inverse correlation with myalgia symptom in COVID-19 patients. Elevation of sFasL protein in serum was associated with reduced lung injury and mortality. Bioinformatics analysis confirmed that blood profile alterations of COVID-19 patients, such as fever and hyponatremia could affect Fas/FasL complex interactions. Our translational findings showed that decreased sFasL is associated with lung involvement; severity and mortality in COVID-19 patients. We think that sFasL is a mediator of neutrophilia and lymphopenia in COVID-19. However, additional investigation is suggested. This is the first report describing that the serum sFasL protein is a severity and mortality prognostic marker for the clinical management of COVID-19 patients. Frontiers Media S.A. 2022-08-31 /pmc/articles/PMC9471328/ /pubmed/36119078 http://dx.doi.org/10.3389/fimmu.2022.947401 Text en Copyright © 2022 Saleki, Shirzad, Javanian, Mohammadkhani, Alijani, Miri, Oladnabi and Azadmehr https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Saleki, Kiarash Shirzad, Moein Javanian, Mostafa Mohammadkhani, Sheyda Alijani, Mohammad Hossein Miri, Niloufarsadat Oladnabi, Morteza Azadmehr, Abbas Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients |
title | Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients |
title_full | Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients |
title_fullStr | Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients |
title_full_unstemmed | Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients |
title_short | Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients |
title_sort | serum soluble fas ligand is a severity and mortality prognostic marker for covid-19 patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471328/ https://www.ncbi.nlm.nih.gov/pubmed/36119078 http://dx.doi.org/10.3389/fimmu.2022.947401 |
work_keys_str_mv | AT salekikiarash serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients AT shirzadmoein serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients AT javanianmostafa serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients AT mohammadkhanisheyda serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients AT alijanimohammadhossein serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients AT miriniloufarsadat serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients AT oladnabimorteza serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients AT azadmehrabbas serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients |